Integrating APOL1 Kidney-risk Variant Testing in Live Kidney Donor Evaluation: An Expert Panel Opinion.
Integrating APOL1 Kidney-risk Variant Testing in Live Kidney Donor Evaluation: An Expert Panel Opinion.
复制标题
DOI：
10.1097/tp.0000000000003641
复制
发表时间：
2021-10-01
期刊：
影响因子：
6.2
通讯作者：
Thomas CP
中科院分区：
文献类型：
--
作者：
Doshi MD;Gordon EJ;Freedman BI;Glover C;Locke JE;Thomas CP
JEL得到了NIDDK-U01DK115997 （co-PI）、R01DK113980 （PI）和K23DK103918 （PI）的资助。MDD和BIF由NIH拨款U01DK116041-01 （PI）支持。EJG得到了NIDDK-R01DK104876 （co-PI）和NIDDK-R01 DK118425 （co-I）的资助。BIF是阿斯利康和RenalytixAI的顾问。BIF和维克森林大学健康科学拥有一项涉及APOL1基因检测的美国专利。其他作者声明没有利益冲突。MDD和CPT作为工作组领导参与，并撰写和审查了手稿。EJG、BIF和JEL撰写并审阅了这篇文章。CG审阅了这篇文章。
JEL was supported by the following grants from NIDDK-U01DK115997 (co-PI), R01DK113980 (PI), and K23DK103918 (PI). MDD and BIF were supported by NIH grant U01DK116041-01 (PI). EJG was supported by the following grants from NIDDK-R01DK104876 (co-PI) and NIDDK-R01 DK118425 (co-I).BIF is a Consultant for AstraZeneca and RenalytixAI. BIF and Wake Forest University Health Sciences have rights to an issued US patent involving APOL1 gene testing. The other authors declare no conflicts of interest. MDD and CPT participated as work-group leaders and wrote and reviewed the manuscript. EJG, BIF, and JEL wrote and reviewed the article. CG reviewed the article.